Briumvi
Briumvi ingredients
| Active ingredient | Strength |
|---|---|
| Ublituximab | 150 mg/6mL |
What Briumvi is used for
The FDA lists the approved uses on the official label (below). In the EU, ublituximab is approved as Briumvi for:
Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Briumvi
- Generic name
- Ublituximab
- Made by
- TG Therapeutics, Inc.
- Forms
- Injection, Solution, Concentrate
- Given
- Intravenous
- Drug class
- CD20-directed Cytolytic Antibody
- FDA approval
- Biologic licence (BLA) BLA761238
- On the US market since
- 2022
Official information
- Briumvi prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Ublituximab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Briumvi?
Briumvi (Ublituximab) is a cancer medicine made by TG Therapeutics, Inc., approved by the US FDA.
What are the ingredients of Briumvi?
Briumvi contains Ublituximab (150 mg/6mL).
Is Briumvi approved in Europe?
The same active substance is approved in the EU as Briumvi.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA